Cassava Sciences Files 8-K Report
Ticker: FLNA · Form: 8-K · Filed: Dec 3, 2025 · CIK: 1069530
| Field | Detail |
|---|---|
| Company | Cassava Sciences INC (FLNA) |
| Form Type | 8-K |
| Filed Date | Dec 3, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, filing, other-events
TL;DR
Cassava Sciences dropped an 8-K, likely with news. Check it out.
AI Summary
On November 26, 2025, Cassava Sciences, Inc. filed an 8-K report. The filing indicates that the company is providing information under 'Other Events'. Specific details regarding the nature of these events, any associated financial implications, or involved parties are not elaborated upon in the provided text excerpt.
Why It Matters
This filing signals a material event or change for Cassava Sciences, Inc. that requires public disclosure, potentially impacting investors' understanding of the company's current status.
Risk Assessment
Risk Level: medium — An 8-K filing indicates a significant event, but the lack of specific details in the provided text makes it difficult to assess the precise risk level.
Key Numbers
- 001-41905 — Commission File Number (SEC file number for Cassava Sciences, Inc.)
- 91-1911336 — I.R.S. Employer Identification Number (EIN for Cassava Sciences, Inc.)
Key Players & Entities
- Cassava Sciences, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- Austin, Texas (location) — Principal executive offices
- November 26, 2025 (date) — Date of earliest event reported
FAQ
What specific 'Other Events' are being reported by Cassava Sciences, Inc. in this 8-K filing?
The provided text excerpt does not specify the nature of the 'Other Events' reported in the 8-K filing.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on November 26, 2025.
What is the principal executive office address for Cassava Sciences, Inc.?
The principal executive office address for Cassava Sciences, Inc. is 6801 N Capital of Texas Highway, Building 1; Suite 300, Austin, Texas 78731.
Under which section of the Securities Exchange Act of 1934 is this 8-K report filed?
This 8-K report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What was Cassava Sciences, Inc.'s former company name?
Cassava Sciences, Inc.'s former company name was PAIN THERAPEUTICS INC.
Filing Stats: 517 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-12-03 06:27:22
Key Financial Figures
- $0.001 — ge on which registered Common Stock , $0.001 par value SAVA NASDAQ Capital Market
Filing Documents
- sava20251201_8k.htm (8-K) — 26KB
- 0001437749-25-036710.txt ( ) — 156KB
- sava-20251126.xsd (EX-101.SCH) — 3KB
- sava-20251126_def.xml (EX-101.DEF) — 12KB
- sava-20251126_lab.xml (EX-101.LAB) — 15KB
- sava-20251126_pre.xml (EX-101.PRE) — 12KB
- sava20251201_8k_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. As previously reported, Cassava Sciences, Inc. (the "Company") has submitted an investigational new drug ("IND") application to the U.S. Food and Drug Administration ("FDA") in support of a proposed proof-of-concept clinical trial for simufilam in tuberous sclerosis complex ("TSC")-related epilepsy. Following an initial notification on November 26, 2025, FDA informed the Company on December 2, 2025, that the agency requires additional information in order to assess the risks to human subjects and to provide sufficient support for the initiation of the proposed clinical study. The Company expects to receive a formal letter from FDA with detailed information regarding the issues identified by FDA and the steps that would need to be taken to address those issues. Cassava will work collaboratively with FDA to provide the agency with the information it requests. The Company continues to prepare to initiate the proof-of-concept study in the first half of 2026. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CASSAVA SCIENCES, INC. a Delaware corporation Date: December 3, 2025 By: /s/ ERIC J. SCHOEN Eric J. Schoen Chief Financial Officer